Testing for drug hypersensitivity syndromes

Clinical Biochemist Reviews

Volumn 34, Issue 1, 2013, Pages 15-38

  Rive, Craig M ^a   Bourke, Jack ^b   Phillips, Elizabeth J ^a,b,c,d  

^a MURDOCH UNIVERSITY   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887318020     PISSN: 01598090     EISSN: 18380212     Source Type: Journal    
DOI: None     Document Type: Article

References (139)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence ofadverse drug reactions in hospitalized patients: a metaanalysisof prospective studies. JAMA 1998;279: 1200-5.
2. Phillips E, Mallal S. HLA and Disease. In: Mehra N, editor. The HLA Complex in Biology and Medicine: A Resource Book. 1st ed. New Delhi, India: JaypeeBrothers Medical Publishers; 2010. p. 333-49.
3. Pichler WJ. Drug Hypersensitivity Reactions: Classification and Relationship to T-Cell Activation. In: Pichler W, editor. Drug Hypersensitivity. 1st ed. Basel, Switzerland: S Karger Pub; 2007. p. 168-89.
4. Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med ClinNorth Am 2010;94:645-64,xv.
5. Gell PGH, Coombs RRA. The classification of allergicreactions underlying disease. In: Gell PGH, CoombsRRA, editors. Clinical Aspects of Immunology. 2nd ed. Oxford: Blackwell Scientific; 1963. p. 317-37.
6. Bircher A, Scherer Hofmeier K. Drug hypersensitivityreactions: Inconsistency in the use of the classificationof immediate and nonimmediate reactions. J AllergyClin Immunol 2012;129:263-4.
7. Uzzaman A, Cho SH. Chapter 28: Classificationof hypersensitivity reactions. Allergy Asthma Proc 2012;33(SUPPL 1):S96-9.
8. Schnyder B, Pichler WJ. Mechanisms of drug-inducedallergy. Mayo Clin Proc 2009;84:268-72.
9. Baldo BA, Pham NH. Histamine-releasing andallergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care 2012;40: 216-35.
10. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity tononsteroidal anti-inflammatory drugs (NSAIDs)-classification, diagnosis and management: review ofthe EAACI/ENDA and GA2LEN/HANNA. Allergy 2011;66:818-29.
11. Kränke B, Aberer W. Skin testing for IgE-mediated drugallergy. Immunol Allergy Clin North Am 2009;29:503-16.
12. Liccardi G, D'Amato G, Canonica GW, Salzillo A, Piccolo A, Passalacqua G. Systemic reactions fromskin testing: literature review. J Investig Allergol ClinImmunol 2006;16:75-8.
13. Brockow K, Ring J. Anaphylaxis to radiographiccontrast media. Curr Opin Allergy Clin Immunol 2011;11:326-31.
14. Sogn DD, Evans R 3rd, Shepherd GM, Casale TB, Condemi J, Greenberger PA, et al. Results of the NationalInstitute of Allergy and Infectious Diseases CollaborativeClinical Trial to test the predictive value of skin testingwith major and minor penicillin derivatives in hospitalizedadults. Arch Intern Med 1992;152:1025-32.
15. Fox S, Park MA. Penicillin skin testing in the evaluationand management of penicillin allergy. Ann AllergyAsthma Immunol 2011;106:1-7.
16. Torres MJ, Blanca M. The complex clinicalpicture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, andclavams. Med Clin North Am 2010;94:805-20,xii.
17. Greenberger PA. Chapter 30: Drug allergy. AllergyAsthma Proc 2012;33(Suppl 1):S103-7.
18. Romano A, Gaeta F, Valluzzi RL, Caruso C, RumiG, Bousquet PJ. IgE-mediated hypersensitivity tocephalosporins: cross-reactivity and tolerability ofpenicillins, monobactams, and carbapenems. J AllergyClin Immunol 2010;126:994-9.
19. Blanca M, Romano A, Torres MJ, Férnandez J, Mayorga C, Rodriguez J, et al. Update on the evaluationof hypersensitivity reactions to betalactams. Allergy 2009;64:183-93.
20. Mertes PM, Aimone-Gastin I, Guéant-RodriguezRM, Mouton-Faivre C, Audibert G, O'Brien J, et al. Hypersensitivity reactions to neuromuscular blockingagents. Curr Pharm Des 2008;14:2809-25.
21. Khan DA, Solensky R. Drug allergy. J Allergy ClinImmunol 2010;125(Suppl 2):S126-37.
22. Torres MJ, Canto G. Hypersensitivity reactions tocorticosteroids. Curr Opin Allergy Clin Immunol 2010;10:273-9.
23. Messaad D, Sahla H, Benahmed S, Godard P, BousquetJ, Demoly P. Drug provocation tests in patients with ahistory suggesting an immediate drug hypersensitivityreaction. Ann Intern Med 2004;140:1001-6.
24. Bousquet PJ, Gaeta F, Bousquet-Rouanet L, Lefrant JY, Demoly P, Romano A. Provocation tests in diagnosingdrug hypersensitivity. Curr Pharm Des 2008;14: 2792-802.
25. Aberer W, Bircher A, Romano A, Blanca M, CampiP, Fernandez J, et al; European Network for DrugAllergy (ENDA); EAACI interest group on drughypersensitivity. Drug provocation testing in thediagnosis of drug hypersensitivity reactions: generalconsiderations. Allergy 2003;58:854-63.
26. Rerkpattanapipat T, Chiriac AM, Demoly P. Drugprovocation tests in hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2011;11:299-304.
27. Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, TorresMJ, Blanca M, et al. Relevance of the determinationof serum-specific IgE antibodies in the diagnosis ofimmediate β-lactam allergy. Allergy 2007;62:47-52.
28. Gómez E, Torres MJ, Mayorga C, Blanca M. Immunologic evaluation of drug allergy. AllergyAsthma Immunol Res 2012;4:251-63.
29. Sampson HA. Update on food allergy. J Allergy ClinImmunol 2004;113:805-19.
30. Mayorga C, Sanz ML, Gamboa PM, García BE, Caballero MT, García JM, et al; ImmunologyCommittee of the Spanish Society of Allergology andClinical Immunology of the SEAIC. In vitro diagnosisof immediate allergic reactions to drugs: an update. JInvestig Allergol Clin Immunol 2010;20:103-9.
31. Guéant JL, Guéant-Rodriguez RM, Viola M, ValluzziRL, Romano A. IgE-mediated hypersensitivity tocephalosporins. Curr Pharm Des 2006;12:3335-45.
32. Leysen J, Sabato V, Verweij MM, De Knop KJ, BridtsCH, De Clerck LS, et al. The basophil activation testin the diagnosis of immediate drug hypersensitivity. Expert Rev Clin Immunol 2011;7:349-55.
33. Hausmann OV, Gentinetta T, Bridts CH, Ebo DG. Thebasophil activation test in immediate-type drug allergy. Immunol Allergy Clin North Am 2009;29:555-66.
34. Roujeau JC. Clinical heterogeneity of drughypersensitivity. Toxicology 2005;209:123-9.
35. Hunziker T, Künzi UP, Braunschweig S, Zehnder D, Hoigné R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997;52:388-93.
36. Lee A, Thomson J. Drug-induced skin reactions. In: LeeA, editor. Adverse Drug Reactions. 2nd ed. London, UK: Pharmaceutical Press; 2006. p. 126-55.
37. Pellicano R, Lomuto M, Ciavarella G, Di Giorgio G, Gasparini P. Fixed drug eruptions with feprazone arelinked to HLA-B22. J Am Acad Dermatol 1997;36: 782-4.
38. Ozkaya-Bayazit E, Akar U. Fixed drug eruption inducedby trimethoprim-sulfamethoxazole: evidence for a linkto HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol 2001;45:712-7.
39. Andrade P, Brinca A, Gonçalo M. Patch testing in fixeddrug eruptions--a 20-year review. Contact Dermatitis 2011;65:195-201.
40. Shiohara T. Fixed drug eruption: pathogenesis anddiagnostic tests. Curr Opin Allergy Clin Immunol 2009;9:316-21.
41. Kaplowitz N. Idiosyncratic drug hepatotoxicity. NatRev Drug Discov 2005;4:489-99.
42. Walsh SA, Creamer D. Drug reaction with eosinophiliaand systemic symptoms (DRESS): a clinical updateand review of current thinking. Clin Exp Dermatol 2011;36:6-11.
43. Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in druginducedhypersensitivity syndrome. Br J Dermatol 2006;155:344-9.
44. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, et al. Association ofhuman herpesvirus 6 infection with drug reaction witheosinophilia and systemic symptoms. Arch Dermatol 2001;137:301-4.
45. Gupta A, Eggo MC, Uetrecht JP, Cribb AE, DanemanD, Rieder MJ, et al. Drug-induced hypothyroidism: thethyroid as a target organ in hypersensitivity reactions toanticonvulsants and sulfonamides. Clin Pharmacol Ther 1992;51:56-67.
46. Eshki M, Allanore L, Musette P, Milpied B, GrangeA, Guillaume JC, et al. Twelve-year analysis of severecases of drug reaction with eosinophilia and systemicsymptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009;145:67-72.
47. Kano Y, Shiohara T. The variable clinical picture ofdrug-induced hypersensitivity syndrome/drug rashwith eosinophilia and systemic symptoms in relationto the eliciting drug. Immunol Allergy Clin North Am 2009;29:481-501.
48. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, NaldiL, Roujeau JC. Clinical classification of cases of toxicepidermal necrolysis, Stevens-Johnson syndrome, anderythema multiforme. Arch Dermatol 1993;129:92-6.
49. Solensky R, Khan DA; Joint Task Force on PracticeParameters; American Academy of Allergy, Asthmaand Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updatedpractice parameter. Ann Allergy Asthma Immunol 2010;105:259-73.
50. Harr T, French LE. Toxic epidermal necrolysis andStevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39.
51. Pavlos R, Phillips EJ. Individualization of antiretroviraltherapy. Pharmacogenomics Pers Med 2012;5:1-17.
52. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, RoujeauJ-C. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol 2001;28:113-9.
53. Beylot C, Doutre M-S, Beylot-Barry M. Acutegeneralized exanthematous pustulosis. Semin CutanMed Surg 1996;15:244-9.
54. Pavlos R, Mallal S, Phillips E. HLA and pharmacogeneticsof drug hypersensitivity. Pharmacogenomics 2012;13:1285-306.
55. Bodmer WF, Bodmer JG. Evolution and function of theHLA system. Br Med Bull 1978;34:309-16.
56. Stenzel A, Lu T, Koch WA, Hampe J, Guenther SM, DeLa Vega FM, et al. Patterns of linkage disequilibrium inthe MHC region on human chromosome 6p. Hum Genet 2004;114:377-85.
57. Phillips EJ, Keane N, Blyth C. Both HLA class I restrictedCD8+ and class II restricted CD4+ T Cells are implicatedin the pathogenesis of nevirapine hypersensitivity. 51st Interscience Conference on Antimicrobial Agents andChemotherapy; 2011:H1-1399c.
58. Dunckley H. HLA typing by SSO and SSP methods. Methods Mol Biol 2012;882:9-25.
59. Little AM. An Overview of HLA Typing forHematopoietic Stem Cell Transplantation. In: BeksacM, editor. Methods in Molecular Medicine: BoneMarrow and Stem Cell Transplantation. Totowa, NJ: Humana Press; 2007. p. 35-49.
60. Hammond E, Mamotte C, Nolan D, Mallal S. HLA-B*5701 typing: evaluation of an allele-specificpolymerase chain reaction melting assay. TissueAntigens 2007;70:58-61.
61. Profaizer T, Eckels D. HLA alleles and drughypersensitivity reactions. Int J Immunogenet 2012;39:99-105.
62. Phillips EJ, Mallal SA. Pharmacogenetics of drughypersensitivity. Pharmacogenomics 2010;11:973-87.
63. Nolan D, Thorborn D, Schaefer M, Laird R, Rauch A, Montaner J, et al. Genetic factors predicting abacavirhypersensitivity and tolerance in HLA-B*5701 positiveindividuals. Eur J Dermatol 2008;18:247.
64. Wolkenstein P, Chosidow O, Fléchet ML, Robbiola O, Paul M, Dumé L, et al. Patch testing in severe cutaneousadverse drug reactions, including Stevens-Johnsonsyndrome and toxic epidermal necrolysis. ContactDermatitis 1996;35:234-6.
65. Alanko K. Patch testing in cutaneous reactions causedby carbamazepine. Contact Dermatitis 1993;29:254-7.
66. Osawa J, Naito S, Aihara M, Kitamura K, Ikezawa Z, Nakajima H. Evaluation of skin test reactions in patientswith non-immediate type drug eruptions. J Dermatol 1990;17:235-9.
67. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivitysyndromes associated with abacavir. AIDS 2002;16:2223-5.
68. Kobayashi N, Bauer TW, Togawa D, Lieberman IH, Sakai H, Fujishiro T, et al. A molecular gram stain usingbroad range PCR and pyrosequencing technology: a potentially useful tool for diagnosing orthopaedicinfections. Diagn Mol Pathol 2005;14:83-9.
69. Alanko K. Patch testing in cutaneous reactions causedby carbamazepine. Contact Dermatitis 1993;29:254-7.
70. Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skintesting in the investigation of cutaneous adverse drugreactions. Br J Dermatol 1998;139:49-58.
71. Torres MJ, Mayorga C, Blanca M. Nonimmediateallergic reactions induced by drugs: pathogenesis anddiagnostic tests. J Investig Allergol Clin Immunol 2009;19:80-90.
72. Rozieres A, Hennino A, Rodet K, Gutowski M-C, Gunera-Saad N, Berard F, et al. Detection andquantification of drug-specific T cells in penicillinallergy. Allergy 2009;64:534-42.
73. Nagao-Dias AT, Teixeira FM, Coelho HL. Diagnosingimmune-mediated reactions to drugs. AllergolImmunopathol (Madr) 2009;37:98-104.
74. Pichler WJ, Tilch J. The lymphocyte transformationtest in the diagnosis of drug hypersensitivity. Allergy 2004;59:809-20.
75. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformationtest in the diagnosis of drug sensitivity: dependenceon its timing and the type of drug eruption. Allergy 2007;62:1439-44.
76. Scheibenbogen C, Lee K-H, Stevanovic S, WitzensM, Willhauck M, Waldmann V, et al. Analysis of theT cell response to tumor and viral peptide antigens byan IFNgamma-ELISPOT assay. Int J Cancer 1997;71: 932-6.
77. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, et al. A sensitive ELISPOT assay todetect low-frequency human T lymphocytes. J ImmunolMethods 1997;210:149-66.
78. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini J-C, et al. Quantitation of antigenreactiveT cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: afour-centre comparative trial. J Immunol Methods 2000;244:81-9.
79. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, WeiCY, et al. Granulysin is a key mediator for disseminatedkeratinocyte death in Stevens-Johnson syndrome andtoxic epidermal necrolysis. Nat Med 2008;14:1343-50.
80. Mallal S, Nolan D, Witt C, Masel G, Martin AM, MooreC, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity toHIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32.
81. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-Bregion and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2.
82. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al; Study of Hypersensitivity to Abacavirand Pharmacogenetic Evaluation Study Team. Highsensitivity of human leukocyte antigen-b*5701 asa marker for immunologically confirmed abacavirhypersensitivity in white and black patients. Clin InfectDis 2008;46:1111-8.
83. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases theincidence of abacavir hypersensitivity reactions in theWestern Australian HIV cohort study. Clin Infect Dis 2006;43:99-102.
84. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, et al. Human leukocyteantigen class I-restricted activation of CD8+ T cellsprovides the immunogenetic basis of a systemic drughypersensitivity. Immunity 2008;28:822-32.
85. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogeneticsand clinical syndromes. J Allergy Clin Immunol 2011;127(Suppl):S60-6.
86. Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, et al; Adverse Drug Reaction Research Group in Korea. Carbamazepine-induced severe cutaneous adversereactions and HLA genotypes in Koreans. Epilepsy Res 2011;97:190-7.
87. Ozeki T, Mushiroda T, Yowang A, Takahashi A, KuboM, Shirakata Y, et al. Genome-wide association studyidentifies HLA-A*3101 allele as a genetic risk factorfor carbamazepine-induced cutaneous adverse drugreactions in Japanese population. Hum Mol Genet 2011;20:1034-41.
88. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactionsin Europeans. N Engl J Med 2011;364:1134-43.
89. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau J-C, Mallal SA. Drug hypersensitivity: pharmacogeneticsand clinical syndromes. J Allergy Clin Immunol 2011;127:S60-6.
90. Lin LC, Lai PC, Yang SF, Yang RC. OxcarbazepineinducedStevens-Johnson syndrome: a case report. Kaohsiung J Med Sci 2009;25:82-6.
91. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, et al. Association of HLA-B*1502 allele andcarbamazepine-induced Stevens-Johnson syndromeamong Indians. Indian J Dermatol Venereol Leprol 2009;75:579-82.
92. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. Association between HLA-B*1502 allele andantiepileptic drug-induced cutaneous reactions in HanChinese. Epilepsia 2007;48:1015-8.
93. Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, et al. Shared and restricted T-cell receptor use is crucialfor carbamazepine-induced Stevens-Johnson syndrome. JAllergy Clin Immunol 2011;128:1266-76,e11.
94. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggeredby drug-modified HLA-peptide repertoire. Nature 2012;486:554-8.
95. Ostrov DA, Grant BJ, Pompeu YA, Sidney J, HarndahlM, Southwood S, et al. Drug hypersensitivity caused byalteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012;109:9959-64.
96. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggeredby drug-modified HLA-peptide repertoire. Nature 2012;486:554-8.
97. Norcross MA, Luo S, Lu L, Boyne MT, Gomarteli M, Rennels AD, et al. Abacavir induces loading of novelself-peptides into HLA-B*57:01: an autoimmunemodel for HLA-associated drug hypersensitivity. AIDS 2012;26:F21-9.
98. Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica 1989;179:32-3.
99. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a geneticmarker for severe cutaneous adverse reactions causedby allopurinol. Proc Natl Acad Sci U S A 2005;102: 4134-9.
100. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong associationbetween HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysisin a Thai population. Pharmacogenet Genomics 2009;19:704-9.
101. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, KimSH, et al; Adverse Drug Reaction Research Group inKorea. Positive and negative associations of HLA classI alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-7.
102. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al; RegiSCAR study group. A Europeanstudy of HLA-B in Stevens-Johnson syndrome andtoxic epidermal necrolysis related to five high-riskdrugs. Pharmacogenet Genomics 2008;18:99-107.
103. Dainichi T, Uchi H, Moroi Y, Furue M. Stevens-Johnsonsyndrome, drug-induced hypersensitivity syndrome andtoxic epidermal necrolysis caused by allopurinol inpatients with a common HLA allele: what causes thediversity? Dermatology 2007;215:86-8.
104. Wang Q, Zhou JQ, Zhou LM, Chen ZY, Fang ZY, ChenSD, et al. Association between HLA-B*1502 alleleand carbamazepine-induced severe cutaneous adversereactions in Han people of southern China mainland. Seizure 2011;20:446-8.
105. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
106. Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Prabmechai N, Vannaprasaht S, et al. HLA-B*1502 strongly predicts carbamazepineinducedStevens-Johnson syndrome and toxic epidermalnecrolysis in Thai patients with neuropathic pain. PainPract 2012;12:202-8.
107. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, et al. Association betweenHLA-B*1502 and carbamazepine-induced severecutaneous adverse drug reactions in a Thai population. Epilepsia 2010;51:926-30.
108. Then SM, Rani ZZ, Raymond AA, RatnaningrumS, Jamal R. Frequency of the HLA-B*1502 allelecontributing to carbamazepine-induced hypersensitivityreactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 2011;29:290-3.
109. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al; JSAR research group. HLA-B*1511 is arisk factor for carbamazepine-induced Stevens-Johnsonsyndrome and toxic epidermal necrolysis in Japanesepatients. Epilepsia 2010;51:2461-5.
110. Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, KaniwaN, Saito Y, et al. HLA class I markers in Japanesepatients with carbamazepine-induced cutaneous adversereactions. Epilepsia 2010;51:297-300.
111. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, et al. Common risk allele in aromaticantiepileptic-drug induced Stevens-Johnson syndromeand toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;11:349-56.
112. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, RevuzJ, Touraine R. Genetic susceptibility to toxic epidermalnecrolysis. Arch Dermatol 1987;123:1171-3.
113. Kim SH, Kim M, Lee KW, Kim SH, Kang HR, ParkHW, et al. HLA-B*5901 is strongly associated withmethazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010;11:879-84.
114. Martin AM, Nolan D, James I, Cameron P, KellerJ, Moore C, et al. Predisposition to nevirapinehypersensitivity associated with HLA-DRB1*0101 andabrogated by low CD4 T-cell counts. AIDS 2005;19:97-9.
115. Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, DistelM, et al; Nevirapine Toxicogenomics Study Team. Toxicogenomics of nevirapine-associated cutaneous andhepatic adverse events among populations of African, Asian, and European descent. AIDS 2011;25:1271-80.
116. Phillips E, Bartlett J, Sanne I, Lederman M, HinkleJ, Rousseau F, et al. Associations between HLADRB1* 0102, HLA-B*5801 and Hepatotoxicity inPatients who Initiated Nevirapine Containing Regimensin South Africa. 18th Conference on Retroviruses andOpportunistic Infections; MA, USA2011.
117. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, et al. HLA-Cw8 primarily associated withhypersensitivity to nevirapine. AIDS 2007;21:264-5.
118. Littera R, Carcassi C, Masala A, Piano P, Serra P, OrtuF, et al. HLA-dependent hypersensitivity to nevirapinein Sardinian HIV patients. AIDS 2006;20:1621-6.
119. Gao S, Gui XE, Liang K, Liu Z, Hu J, Dong B. HLAdependenthypersensitivity reaction to nevirapine inChinese Han HIV-infected patients. AIDS Res HumRetroviruses 2012;28:540-3.
120. Alfirevic A, Jorgensen AL, Williamson PR, ChadwickDW, Park BK, Pirmohamed M. HLA-B locus inCaucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-8.
121. Vitezica ZG, Milpied B, Lonjou C, Borot N, LedgerTN, Lefebvre A, et al. HLA-DRB1*01 associated withcutaneous hypersensitivity induced by nevirapine andefavirenz. AIDS 2008;22:540-1.
122. Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Tunthanathip P, et al. HLA-Cw*04 allele associated with nevirapine-inducedrash in HIV-infected Thai patients. AIDS Res Ther 2009;6:22.
123. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, et al. HLA-B*3505 allele is a strong predictor fornevirapine-induced skin adverse drug reactions inHIV-infected Thai patients. Pharmacogenet Genomics 2009;19:139-46.
124. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, etal. Genome-wide association study identifies variationsin 6p21.3 associated with nevirapine-induced rash. ClinInfect Dis 2011;53:341-8.
125. Romano A, De Santis A, Romito A, Di Fonso M, VenutiA, Gasbarrini GB, et al. Delayed hypersensitivity toaminopenicillins is related to major histocompatibilitycomplex genes. Ann Allergy Asthma Immunol 1998;80:433-7.
126. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepineinducedcutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306.
127. Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D. Phenytoin-induced Stevens-Johnson syndrome withnegative HLA-B*1502 allele in mainland China: twocases. Seizure 2011;20:431-2.
128. Pellicano R, Ciavarella G, Lomuto M, Di Giorgio G. Genetic susceptibility to fixed drug eruption: evidencefor a link with HLA-B22. J Am Acad Dermatol 1994;30:52-4.
129. Hautekeete ML, Horsmans Y, Van Waeyenberge CD, Demanet C, Henrion J, Verbist L, et al. HLA associationof amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999;117:1181-6.
130. Lucena MI, Molokhia M, Shen YU, Urban TJ, Aithal GP, Andrade RJ, et al; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; InternationalSAEC. Susceptibility to amoxicillin-clavulanateinducedliver injury is influenced by multiple HLAclass I and II alleles. Gastroenterology 2011;141: 338-47.
131. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class IIassociation. Gut 2000;47:717-20.
132. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLAalleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42:711-4.
133. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-widepharmacogenetic investigation of a hepatic adverse eventwithout clinical signs of immunopathology suggests anunderlying immune pathogenesis. Pharmacogenomics J 2008;8:186-95.
134. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, DangTS, Day CP. Genetic susceptibility to diclofenac-inducedhepatotoxicity: contribution of UGT2B7, CYP2C8, andABCC2 genotypes. Gastroenterology 2007;132:272-81.
135. Daly AK, Day CP. Genetic association studies in druginducedliver injury. Semin Liver Dis 2009;29:400-11.
136. Daly AK, Day CP. Genetic association studies in druginducedliver injury. Drug Metab Rev 2012;44:116-26.
137. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'erI, Floratos A, et al; DILIGEN Study; InternationalSAE Consortium. HLA-B*5701 genotype is a majordeterminant of drug-induced liver injury due toflucloxacillin. Nat Genet 2009;41:816-9.
138. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1*02:01 is a major risk factorfor lapatinib-induced hepatotoxicity in women withadvanced breast cancer. J Clin Oncol 2011;29:667-73.
139. Kardaun SH, de Monchy JG. Acute generalizedexanthematous pustulosis caused by morphine, confirmedby positive patch test and lymphocyte transformationtest. J Am Acad Dermatol 2006;55(Suppl):S21-3.